Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of RET tyrosine kinase by SU5416

1 Oct 2006

Abstract excerpt

Thyroid neoplasia is frequently associated with rearranged during transfection (RET) proto-oncogene mutations that cause hyperactivation of RET kinase activity. Selective inhibition of RET-mediated signaling should lead to an efficacious therapy. SU5416 is a potent inhibitor of vascular endothelial cell growth factor receptor, c-Kit, and FLT-3 receptor tyrosine kinases presently used in clinical trials. We found...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
Share to Thyroid Cancer Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17032739
DOI: 10.1677/jme.1.01999

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of RET tyrosine kinase by SU5416PMID 17032739Read ↗

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.Semantic proximity Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation.Semantic proximity Read ↗

Development of RET Kinase Inhibitors for Targeted Cancer TherapySemantic proximity Read ↗

Discovery of CN-3 as a Next-Generation RET Inhibitor Potently Overcoming Multiple Mutations.Semantic proximity Read ↗

Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.Semantic proximity Read ↗

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.Semantic proximity Read ↗

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read ↗

RET signaling pathway and RET inhibitors in human cancerSemantic proximity Read ↗

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.Semantic proximity Read ↗

Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.Semantic proximity Read ↗

Targeting RET Receptor Tyrosine Kinase Activation in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.